Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-09-12
2006-09-12
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093200, C435S325000, C435S005000, C435S006120, C435S007100, C435S007200, C435S069100, C435S455000, C435S458000, C435S372000, C435S372300, C536S023100
Reexamination Certificate
active
07105157
ABSTRACT:
The present invention relates to cells and methods for treating or preventing tumor formation or infections with pathogens in a patient. The cells of the invention are antigen-presenting cells (e.g., dendritic cells or macrophage) that have been loaded with RNA derived from tumors or pathogens. By administering the RNA-loaded antigen-presenting cells to a patient, tumor formation or pathogen infections can be treated or prevented. Alternatively, the RNA-loaded cells can be used as stimulator cells in the ex vivo expansion of CTL. Such CTL can then be used in a variation of conventional adoptive immunotherapy techniques.
REFERENCES:
patent: 4918164 (1990-04-01), Hellstrom et al.
patent: 5256536 (1993-10-01), Miyada et al.
patent: 5662907 (1997-09-01), Kubo et al.
patent: 5827642 (1998-10-01), Riddell et al.
patent: 5830877 (1998-11-01), Carson et al.
patent: 5831068 (1998-11-01), Nair et al.
patent: 5853719 (1998-12-01), Nair et al.
patent: 6130087 (2000-10-01), Srivastava et al.
patent: 6228640 (2001-05-01), Cezayirli et al.
patent: 6306388 (2001-10-01), Nair et al.
patent: 6387701 (2002-05-01), Nair et al.
patent: 6670186 (2003-12-01), Nair et al.
patent: WO 94/04171 (1994-03-01), None
patent: WO 94/04557 (1994-03-01), None
patent: WO 95/34638 (1995-12-01), None
patent: WO 97/41210 (1997-11-01), None
Michael B. A. Oldstone et al, How Viruses Escaqpe from Cytotoxic T Lymphocytes: Molecular Parameters and Players, Virology 234, 179-185 (1997). Article No. VY978674.
Drew M. Pardoll, Cancer vaccines, Nature Medicine Vaccine Supplement, vol. 4, No. 5, May 1998.
N. Regina Rabinovich et al,Bumps on the Vaccine Road, Science . vol. 265, Sep. 1994.
Trisha Gura, Cancer Models, Systems for Identifying New Drugs Are Often Faulty, Science, vol. 278, Nov. 1997.
N. Regina Rabinovich et al, Vaccine Technologies: View to the Future, Science. vol. 265. Sep. 1994.
Arnaud Morel et al, Does preventive vaccination with engineered tumor cells work in cancer-prone transgenic mice?, Cancer Gene Therapy, vol. 5, No. 2, 1998: pp. 92-100.
J. Gomez-Navarro et al, Gene Therapy for Cancer, European Journal of Cancer, vol. 35, No. 6, pp. 867-885, 1999.
Jonathan Sprent et al, Lymphocyte Life-Span and Memory, Science. vol. 265. Sep. 1994.
Richard J.D. Rouse et al, Induction In Vitro of Primary Cytotoxic T-Lymphocyte Responses with DNA Encoding Herpes Simplex Virus Proteins, Journal of Virology, Sep. 1994, p. 5685-5689.
Stanley R. Riddeell et al, Class 1 MHC—Restricted Cytotoxic T Lymphocyte Recognition Of Cells Infected With Human Cytomegalovirus Does Not Require Endogenous Viral Gene Expression, The Journal of Immunology, vol. 146,2795-2804, No. 8., Apr. 15, 1991.
David Boczkowski et al, Dendritic Cells Pulsed with RNA are Potent Antigen-presenting cells In Vitro and In Vivo, vol. 184, Aug. 1996, 465-472.
U.S. Provisional Appl. No. 60/038,736.
U.S. Provisional Appl. No. 60/042,110.
Kim, et al. Interleukin-secreting Mouse Fibroblasts Transfected with Genomic DNA from Murine Melanoma Cells Prolong the Survival of Mice with Melanoma. Cancer Research. May 15, 1994, vol. 54, pp. 2531-2535.
Bhoopalam et al. Surface Immunoglobulins of Circulating Lymphocytes in Mouse Plasmacytoma. II. The Influence of Plasmacytoma RNA on Surface Immunoglobulins of Lymphocites. Blood. Apr. 1972, vol. 39, No. 4, pp. 465-471.
Villarreal, L.P. et al. Common Mechanisms of Transformation by Small DNA Tumor Viruses. Washington, D. C.: American Society of Microbiology. 1989, Chapter 1, pp. 1-17.
Crusinberry et al, “Immunotherapy of Renal Cell Cancer”, Seminars in Surgical Oncology 7:221-229 (1991).
Rosenberg et al, “Use of Tumor-Infiltrating Lymphocytes and Interelukin-2 in the Immunotherapy of Patients With Metastatic Melanoma”, The New England Journal of Medicine 319(25):1676-1680 (1998).
Donis-Keller, H., “Site specific enzymatic cleavage of RNA”, Nucleic Acids Research 7(1):179-192 (1979).
Friedman, H., “Discussion Paper: Protective Immunity in Leukemic Mice Treated with Specific “Immunogenic” RNA”, Annals New York Academy of Sciences 277(00):708-715 (1976).
Greenup et al, “Anti-Tumor Cytotoxicity of Poly(A)-Containing Messenger RNA Isolated From Tumour-Specific Immunogenic RNA”, Br. J. Cancer 38:55-63 (1978).
Aarons et al, “Immune RNA Therapy as an Effective Adjuvant Immunotherapy After Surgery: An Animal Model” , Journal of Surgical Oncology 23:21-26 (1983).
Porgador et al, “Combined Vaccination with Major Histocompatibility Class I and Interleukin 2 Gene-transduced Melanoma Cells Synergizes the Cure of Postsurgical Established Lung Metastases”, Cancer Research 55:4941-4949 (1995).
Rötzschke et al, “Exact prediction of a natural T cell epitope”, Eur. J. Immunol. 21:2891-2894 (1991).
van den Bosch et al, “T-Cell-Independent Macrophase Activation in Mice Induced with rRNA fromListeria monocytogenesand Dimethyldioctadecylammonium Bromide”, Infection and Immunity 53(3):611-615 (1986).
Boon et al, “Human Tumor Antigens Recognized by T Lymphocytes”, J. Exp. Med. 183:725-729 (1996).
Rifkind et al, “Delayed Hypertensitivity to Fungal Antigens in Mice. II. Molecular Classes in Immunogenic RNA Extracts that Transfer Delayed Hypersensitivy”, The Journal of Infectious Diseases 133(5):523-532 (1976).
Rifkind et al, “Delayed Hypersensivity to Fungal Antigens in Mice III. Characterization of the Acitve Component in Immunogenic RNA Extracts”, The Journal of Infectious Diseases 133(5):533-537 (1976).
Nair et al, “Cells Treated with TAP-2 Antisense Oligonucleotides Are Potent Antigen-Presenting Cells In Vitro and In Vivo”, The Journal of Immunology 156:1772-1780 (1996).
Inada et al, “Comparison of the Ability of Lactate Dehydrogenase-Elevating Virus and Its Virion RNA To Infect Murine Leukemia Virus-Infected or -Uninfected Cell Lines”, Journal of Virology 67(9):5698-5703 (1993).
Duke et al, “In Vitro Induction of Antibody Formation With Immunogenic RNA”, Annals New York Academy of Sciences 207:145-159 (1973).
Garvey et al, “Characterization of RNA-Antigen Complexes”, Annals New York Academy of Sciences 207:258-278 (1973).
Dodd et al, “Immunogenic RNA in the Immunotherapy of Cancer: The Transfer of Antitumor Cytotoxic Activity and Tuberculin Sensitivity to Human Lymphocytes Using Xenogeneic Ribonucleic Acid”, Annals New York Academy of Sciences 207:454-467 (1973).
Walker et al, “Cationic lipids direct a viral glycoproteion into the class I major histocompatibility complex antigen-presentation pathway”, Proc. Natl. Acad. Sci. USA 89:7915-7918 (1992).
Vyas et al, “Specific Immunotherapy Proposed for Hepatitis B Virus Infection”, Develop. biol. Standard. 30:350-356 (1975).
Wu et al, “Engineering an intracellular pathway for major histocompatiblity complex class II presentation of antigens”, Proc. Natl. Acad. Sci. USA 92:11671-11675 (1995).
Lin et al, “Treatment of Established Tumors with a Novel Vaccine That Enhances Major Histocompatibility Class II Presentatiion of Tumor Antigen”, Cancer Research 56:21-26 (1996).
Machado et al, “Dialyzable transfer factor in experimental Chagas' disease: in vitro studies”, Trop. Med. Parasit. 37:399-402 (1986).
Slomsky et al, “Induction of Antibody Synthesis In Vitro By Immunogenic RNA”, Annals Med. Sect. Pol. Acad. Sci. 20(4):255-268 (1975).
Paglia et al, “Murine Dendritic Cells Loaded In Vitro with Soluble Protein Prime Cytotoxic T Lymphocytes against Tumor Antigen In Vivo”, J. Exp. Med. 183:317-322 (1996).
Celluzzi et al, “Peptide-pulsed Dendritic Cells Induce Antigen-specific, CTL-mediated Protective Tumor Immunity”, J. Exp. Med. 183:283-287 (1996).
Kormanec and Farkasovsky, “Isolation of total RNA from yeast and bacteria and detection of rRNA in northern blots”, Biotechniques 17(5):838-842 (1994)—Pub Med—PMID: 7530979
Boczkowski David J.
Gilboa Eli
Nair Smita K.
Duke University
Guzo David
Nixon & Vanderhye P.C.
LandOfFree
Methods for treating cancers and pathogen infections using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cancers and pathogen infections using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cancers and pathogen infections using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3608225